Our Medicine

Fyrarro

FYARRO^® is now approved in the United States for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)

For patients and healthcare providers in the United States, you can learn more about FYARRO^® by visiting the product website or downloading the full US Prescribing Information.

Medical Information, Adverse Event and Product Complaint Reporting

For medical information and to report a potential adverse event or product complaint, contact Aadi Bioscience Medical Information by calling 1-888-BIO-AADI (888-246-2234) or emailing medinfo@aadibio.com.

Access Requests

Physicians seeking named patient access to nab-sirolimus on behalf of their patients outside of the US should submit an inquiry to expandedaccess@aadibio.com.

Our Medicine

FYARRO® is now approved in the United States for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)

For patients and healthcare providers in the United States, you can learn more about FYARRO® by visiting the product website or downloading the full US Prescribing Information.

Medical Information, Adverse Event and Product Complaint Reporting

Access Requests

FYARRO^® is now approved in the United States for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)

For patients and healthcare providers in the United States, you can learn more about FYARRO^® by visiting the product website or downloading the full US Prescribing Information.